The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions
Open accessAbstract
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Strategies to reduce cardiac disease by improving chelation regimens have been of the highest priority. These strategies have included development of novel oral iron chelators to improve compliance, improved assessment of cardiac iron status, and careful epidemiologic assessment of European outcomes with deferiprone, an oral alternative chelator available for about a decade. Each of these strategies is now bearing fruit. The novel oral chelator deferasirox was recently approved by the Food and Drug Administration (FDA); a randomized clinical trial demonstrates that deferasirox at 20 to 30 mg/kg/d can maintain or improve hepatic iron in thalassemia as well as deferoxamine. A randomized trial based on cardiac T2* magnetic resonance imaging (MRI) suggests that deferiprone can unload myocardial iron faster than deferoxamine. Retrospective epidemiologic data suggest dramatic reductions in cardiac events and mortality in Italian subjects exposed to deferiprone compared with deferoxamine. These developments herald a new era for iron chelation, but many unanswered questions remain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
Anderson, L. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2822 · Cited by 1,682
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance
St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P., Olynyk, J. K., Pootrakul, P., Robins, E., & Lindeman, R. (2005) · Blood · doi:10.1182/blood-2004-01-0177 · Cited by 909
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717
Pennell, D. J. (2006) · Blood · doi:10.1182/blood-2005-07-2948 · Cited by 495
Anderson, L. J., Wonke, B., Prescott, E., Holden, S., Malcolm Walker, J., & Pennell, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09740-4 · Cited by 430
Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major
Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R. G., McClelland, R. A., Burt, A. D., & Fleming, K. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390701 · Cited by 420
Westwood, M., Anderson, L. J., Firmin, D. N., Gatehouse, P. D., Charrier, C. C., Wonke, B., & Pennell, D. J. (2003) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10332 · Cited by 379
Borgna-Pignatti, C. (2006) · Blood · doi:10.1182/blood-2005-07-2933 · Cited by 376
Cited by
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Viral infection and iron metabolism
Drakesmith, H., & Prentice, A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1930 · Cited by 469
Rachmilewitz, E. A., & Giardina, P. J. (2011) · Blood · doi:10.1182/blood-2010-08-300335 · Cited by 417
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
Metadata
- Authors
- Neufeld, E. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-05-01
- Volume
- 107
- Issue
- 9
- Pages
- 3436-3441
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2146921545
- Cited by
- 315
- References
- 30
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. https://app.cochat.ai/papers/10.1182/blood-2006-02-002394
- The paper
- Neufeld, E. J. (2006). Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. https://doi.org/10.1182/blood-2006-02-002394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.